Loading...

Purified anti-human CD16 Antibody

Pricing & Availability
Clone
3G8 (See other available formats)
Regulatory Status
RUO
Workshop
V NK80
Other Names
FcγRIII, Fc gamma receptor, Fc gamma receptor 3
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
3G8_Pure_071805
Human peripheral blood lymphocytes stained with purified 3G8 and anti-mouse IgGs FITC
  • 3G8_Pure_071805
    Human peripheral blood lymphocytes stained with purified 3G8 and anti-mouse IgGs FITC
Compare all formats
Cat # Size Price Quantity Check Availability Save
302001 25 µg 65 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302002 100 µg 110 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC).

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
African Green, Baboon, Capuchin Monkey, Chimpanzee, Common Marmoset, Pigtailed Macaque, Sooty Mangabey, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human PMN cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/mL
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF® - Verified
Block, IHC-F, IP, Stim - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The 3G8 antibody clone blocks neutrophil phagocytosis and stimulates NK cell proliferation. It has been reported that this clone interacts with the FcγRIIa and FcγRIIIb receptors causing neutrophil activation and aggregation18. Due to this phenomenon staining in whole blood may cause a reduction in the number of granulocytes or alter their scatter profile.

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections6, immunoprecipitation3, stimulation of NK cell proliferation4, blocking of phagocytosis5, and blocking of immunoglobulin binding to FcγRIII7,8. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302049, 302050, 302057, 302058).

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  3. Edberg J, et al. 1997. J. Immunol. 159:3849. (IP)
  4. Hoshino S, et al. 1991. Blood 78:3232. (Stim)
  5. Tamm A, et al. 1996. Immunol. 157:1576. (Block)
  6. Da Silva DM, et al. 2001. Int. Immunol. 13:633. (IHC)
  7. Holl V, et al. 2004. J. Immunol. 173:6274. (Block)
  8. Hober D, et al. 2002. J. Gen. Virol. 83:2169. (Block)
  9. Brainard DM, et al. 2009. J. Virol. 83:7305. PubMed
  10. Smed-Sörensen A, et al. 2008. Blood 111:5037. (Block) PubMed
  11. Timmerman KL, et al. 2008. J. Leukoc. Biol. 84:1271. (FC) PubMed
  12. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  13. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  14. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
  15. Boltz A, et al. 2011. J. Biol Chem. 286:21896. PubMed
  16. Wu Z, et al. 2013. J. Virol. 87:7717. PubMed
  17. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  18. Vossebeld PJ, et al. 1997. Biochem J. 323:87-94 (Stim)
Product Citations
  1. Dallari S, et al. 2017. Nat Commun. 8:14830. PubMed
  2. Miyamoto DT, et al. 2018. Cancer Discov. 0.533333333. PubMed
  3. Weinhage T, et al. 2020. J Immunol. 205:56. PubMed
  4. Wu Z, et al. 2013. J Virol. 87:7717. PubMed
  5. Wagner J et al. 2019. Cell. 177(5):1330-1345 . PubMed
  6. Korn MA, et al. 2020. J Immunol. 205:2595. PubMed
  7. Friedman D, et al. 2021. J Cell Sci. 134:. PubMed
  8. Smed-Sörensen A, et al. 2008. Blood. 111:5037. PubMed
  9. Cao Q, et al. 2018. Am J Physiol Renal Physiol. 314:F561. PubMed
  10. Fasbender F, et al. 2017. Front Immunol. 0.88125. PubMed
  11. Holder KA, et al. 2021. Clin Transl Immunology. 10:e1348. PubMed
  12. Santos R, et al. 2017. Nat Commun. . 10.1038/s41467-017-01760-5. PubMed
  13. Mask E, et al. 2022. Front Cell Infect Microbiol. 12:880860. PubMed
  14. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  15. Boltz A, et al. 2011. J Biol Chem. 286:21896. PubMed
  16. Winkler M, et al. 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
  17. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
  18. Li L, et al. 2019. Cell Stem Cell. 24:271. PubMed
  19. Gainers M, et al. 2007. J Immunol. 179:8509. PubMed
  20. Sibener LV et al. 2018. Cell. 174(3):672-687 . PubMed
  21. Okubo K, et al. 2021. Cell Reports. 35(7):109142. PubMed
  22. Urlaub D, et al. 2017. J Immunol. 198:1944. PubMed
  23. Syrimi E, et al. 2021. iScience. 24:103215. PubMed
  24. Jog NR, et al. 2018. Front Immunol. 9:2198. PubMed
  25. Eldredge LC, et al. 2019. Am J Physiol Lung Cell Mol Physiol. 317:L49. PubMed
  26. Olin A, et al. 2018. Cell. 174:1277. PubMed
  27. Farhadian SF, et al. 2022. JCI Insight. 7:. PubMed
  28. Park JE, et al. 2020. Journal for ImmunoTherapy of Cancer. 8(2):e000873.. PubMed
  29. Auladell M, et al. 2019. Clin Transl Immunology. 8:e01090. PubMed
  30. Eccles JD, et al. 2020. Cell Rep. 30:351. PubMed
  31. Prodjinotho UF, et al. 2017. PLoS Negl Trop Dis. 11:e0005777. PubMed
  32. Park YJ, et al. 2022. PLoS Pathog. 18:e1010468. PubMed
  33. Frobel J, et al. 2018. Clin Epigenetics. 10:67. PubMed
  34. Ehinger E, et al. 2021. Cardiovasc Res. 117:1166. PubMed
  35. Mody P, et al. 2007. Blood. 110:2974. PubMed
  36. Ardain A, et al. 2019. Nature. 570:528. PubMed
  37. Li J, et al. 2021. Haematologica. 106:3115. PubMed
  38. Shemesh A, et al. 2022. J Exp Med. 219:. PubMed
  39. Kato M, et al. 2021. PLoS One. 16:e0252116. PubMed
  40. Combes AJ, et al. 2021. Nature. 591:124. PubMed
  41. Steffen U, et al. 2020. Nat Commun. 0.541666667. PubMed
  42. Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed
  43. Pohl K, et al. 2018. PLoS One. 13:e0209026. PubMed
  44. Doni A, et al. 2021. Nat Commun. 12:3739. PubMed
  45. De Maeyer RPH, et al. 2020. Nat Immunol. 21:615. PubMed
  46. Ravindran A, et al. 2018. Front Immunol. 9:2193. PubMed
  47. Farrington LA, et al. 2020. PLoS Pathog. 16:e1008997. PubMed
  48. Edri-Brami M, et al. 2012. PLoS One. 7:e35772. PubMed
  49. Lakshmikanth T, et al. 2020. Cell Reports. 32(3):107923. PubMed
  50. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  51. Sung JA, et al. 2018. Mol Ther. 26:2496. PubMed
  52. Chevrier S, et al. 2018. Cell Syst. 0.675. PubMed
  53. Zhong Q, et al. 2018. J Immunol. 200:3913. PubMed
  54. Ravell JC, et al. 2020. J Clin Invest. 130:507. PubMed
  55. Martin E, et al. 2020. JCI Insight. :5. PubMed
  56. Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed
  57. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
RRID
AB_314201 (BioLegend Cat. No. 302001)
AB_314202 (BioLegend Cat. No. 302002)

Antigen Details

Structure
Ig superfamily, transmembrane form (50-65 kD) or GPI-linked form (48 kD)
Distribution

NK cells, activated monocytes, macrophages, neutrophils

Function
Low affinity IgG Fc receptor, phagocytosis, ADCC
Ligand/Receptor
Aggregated IgG, IgG-antigen complex
Cell Type
Dendritic cells, Macrophages, Monocytes, Neutrophils, NK cells
Biology Area
Immunology, Innate Immunity
Molecular Family
CD Molecules, Fc Receptors
Antigen References

1. Fleit H, et al. 1982. P. Natl. Acad. Sci. USA 79:3275.
2. Stroncek D, et al. 1991. Blood 77:1572.
3. Wirthmueller U, et al. 1992. J. Exp. Med. 175:1381.

Gene ID
2214 View all products for this Gene ID
UniProt
View information about CD16 on UniProt.org

Related FAQs

Is our human Trustain FcX™ (cat# 422302) compatible with anti human CD16, CD32 and CD64 clones 3G8, FUN-2 and 10.1 respectively?

Yes

Other Formats

View All CD16 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD16 3G8 FC
Biotin anti-human CD16 3G8 FC
FITC anti-human CD16 3G8 FC
Brilliant Violet 711™ anti-human CD16 3G8 FC
PE anti-human CD16 3G8 FC
PE/Cyanine5 anti-human CD16 3G8 FC
Purified anti-human CD16 3G8 FC,CyTOF®,Block,IHC-F,IP,Stim
APC/Cyanine7 anti-human CD16 3G8 FC
PE/Cyanine7 anti-human CD16 3G8 FC
Alexa Fluor® 488 anti-human CD16 3G8 FC
Alexa Fluor® 647 anti-human CD16 3G8 FC
Pacific Blue™ anti-human CD16 3G8 FC
Alexa Fluor® 700 anti-human CD16 3G8 FC
PerCP/Cyanine5.5 anti-human CD16 3G8 FC
PerCP anti-human CD16 3G8 FC
Brilliant Violet 421™ anti-human CD16 3G8 FC
Brilliant Violet 570™ anti-human CD16 3G8 FC
Brilliant Violet 605™ anti-human CD16 3G8 FC
Brilliant Violet 650™ anti-human CD16 3G8 FC
Brilliant Violet 785™ anti-human CD16 3G8 FC
Brilliant Violet 510™ anti-human CD16 3G8 FC
Ultra-LEAF™ Purified anti-human CD16 3G8 FC,CyTOF®,Block,IHC-F,IP,Stim
Purified anti-human CD16 (Maxpar® Ready) 3G8 FC,CyTOF®
PE/Dazzle™ 594 anti-human CD16 3G8 FC
APC/Fire™ 750 anti-human CD16 3G8 FC
PE anti-human CD16 3G8 FC
APC anti-human CD16 3G8 FC
Pacific Blue™ anti-human CD16 3G8 FC
PE/Dazzle™ 594 anti-human CD16 3G8 FC
TotalSeq™-A0083 anti-human CD16 3G8 PG
TotalSeq™-B0083 anti-human CD16 3G8 PG
TotalSeq™-C0083 anti-human CD16 3G8 PG
PE/Cyanine7 anti-human CD16 3G8 FC
PE/Fire™ 640 anti-human CD16 3G8 FC
FITC anti-human CD16 3G8 FC
Spark YG™ 581 anti-human CD16 3G8 FC
APC/Fire™ 750 anti-human CD16 3G8 FC
TotalSeq™-D0083 anti-human CD16 3G8 PG
APC/Fire™ 810 anti-human CD16 3G8 FC
GMP APC anti-human CD16 3G8 FC
GMP PE/Dazzle™ 594 anti-human CD16 3G8 FC
GMP PE anti-human CD16 3G8 FC
Spark Red™ 718 anti-human CD16 3G8 FC
GMP Pacific Blue™ anti-human CD16 3G8 FC
GMP FITC anti-human CD16 3G8 FC
Spark Blue™ 515 anti-human CD16 3G8 FC
Go To Top Version: 4    Revision Date: 08.22.2022

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-human CD16

  • Biotin anti-human CD16

  • FITC anti-human CD16

  • Brilliant Violet 711™ anti-human CD16

  • PE anti-human CD16

  • PE/Cyanine5 anti-human CD16

  • Purified anti-human CD16

  • APC/Cyanine7 anti-human CD16

  • PE/Cyanine7 anti-human CD16

  • Alexa Fluor® 488 anti-human CD16

  • Alexa Fluor® 647 anti-human CD16

  • Pacific Blue™ anti-human CD16

  • Alexa Fluor® 700 anti-human CD16

  • PerCP/Cyanine5.5 anti-human CD16

  • PerCP anti-human CD16

  • Brilliant Violet 421™ anti-human CD16

  • Brilliant Violet 570™ anti-human CD16

  • Brilliant Violet 605™ anti-human CD16

  • Brilliant Violet 650™ anti-human CD16

  • Brilliant Violet 785™ anti-human CD16

  • Brilliant Violet 510™ anti-human CD16

  • Ultra-LEAF™ Purified anti-human CD16

  • Purified anti-human CD16 (Maxpar® Ready)

  • PE/Dazzle™ 594 anti-human CD16

  • APC/Fire™ 750 anti-human CD16

  • PE anti-human CD16

  • APC anti-human CD16

  • Pacific Blue™ anti-human CD16

  • PE/Dazzle™ 594 anti-human CD16

  • TotalSeq™-A0083 anti-human CD16

  • TotalSeq™-B0083 anti-human CD16

  • TotalSeq™-C0083 anti-human CD16

  • PE/Cyanine7 anti-human CD16

  • PE/Fire™ 640 anti-human CD16

  • FITC anti-human CD16

  • Spark YG™ 581 anti-human CD16

  • APC/Fire™ 750 anti-human CD16

  • TotalSeq™-D0083 anti-human CD16

  • APC/Fire™ 810 anti-human CD16

  • GMP APC anti-human CD16

  • GMP PE/Dazzle™ 594 anti-human CD16

  • GMP PE anti-human CD16

  • Spark Red™ 718 anti-human CD16

  • GMP Pacific Blue™ anti-human CD16

  • GMP FITC anti-human CD16

  • Spark Blue™ 515 anti-human CD16
ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account